Building Health, Restoring Independence


Targacept has a diverse clinical pipeline built on a unique class of therapeutic targets.

Targacept Inc.

100 North Main Street, Suite 1510

Winston-Salem, NC 27101

Therapeutic Focus:

Nervous system and gastrointestinal/genitourinary diseases and disorders

Therapeutic Targets:

Neuronal nicotinic receptors (NNRs)

Product Candidates:

TC-5214, Overactive Bladder

TC-6499, Diabetic Gastroparesis

AZD1446, TBD

Strategic Alliances:

Global collaboration and license agreement with AstraZeneca AB for AZD1446

Number of Employees:


Date Established:

March 1997

IPO Completed:

April 2006

NASDAQ Ticker Symbol:


Targacept Company Overview – Expertise in the Field of NNRs
Targacept, TRGT, NNR Therapeutics, neuronal nicotinic receptors, NNR, neuronal nicotinic acetylcholine receptors, nicotinic acetylcholine receptors, nAChR, nicotinic, nicotinic agonist, nicotinic antagonist, nervous system disorders, nicotinic channel modulator, central nervous system disorders, CNS, schizophrenia, residual phase schizophrenia, residual symptoms, negative symptoms, cognitive dysfunction, overactive bladder, OAB, Alzheimer’s disease, age associated memory impairment, AAMI, cognition, Parkinson’s disease, l-dopa-induced dyskinesia
Targacept is a leader in NNRs, with more than 20 years of NNR-focused research and development.